CSL Limited

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:37 2024-05-15 am EDT			5-day change	1st Jan Change
283 ^AUD	+1.24%		+1.13%	-1.26%

May. 13	Australian shares end flat as miners offset losses in banks, energy; US CPI on tap	RE
May. 10	Australian shares gain on fresh Fed rate-cut hopes, on track for best week in 5	RE

CSL Limited Reports Earnings Results for the Half Year Ended December 31, 2023

February 12, 2024 at 04:24 pm EST

CSL Limited reported earnings results for the half year ended December 31, 2023. For the half year, the company reported sales was USD 7,804 million compared to USD 6,943 million a year ago. Revenue was USD 8,053 million compared to USD 7,184 million a year ago.

Net income was USD 1,901 million compared to USD 1,623 million a year ago. Basic earnings per share from continuing operations was USD 3.94 compared to USD 3.37 a year ago. Diluted earnings per share from continuing operations was USD 3.92 compared to USD 3.36 a year ago.

Latest news about CSL Limited

Australian shares end flat as miners offset losses in banks, energy; US CPI on tap	May. 13	RE
Australian shares gain on fresh Fed rate-cut hopes, on track for best week in 5	May. 09	RE
Australian shares retreat as miners, banks drag; CBA down on lower profit	May. 08	RE
Australia's CSL tests 'dynamic pricing' of donor blood amid cost surge	May. 06	RE
Commodity stocks lift Australian shares; RBA decision on tap	May. 06	RE
Australian shares rise on US rate cut hopes; RBA in focus	May. 05	RE
Australian shares fall as miners and banks drag; Fed in focus	Apr. 30	RE
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	Apr. 30	CI
Australian shares rise on banks, IT boost; Fed policy meet on tap	Apr. 28	RE
Australian shares tumble as miners, energy stocks fall; BHP Group tanks	Apr. 25	RE
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	Apr. 24	CI
Australian shares climb on banks, energy boost; March-quarter CPI in focus	Apr. 23	RE
Australian shares follow Wall Street higher, miners limit gains	Apr. 22	RE
Australian shares rebound as miners and financials jump; inflation data awaited	Apr. 21	RE
Vifor Pharma offers to rectify anti-competitive behaviour against rival	Apr. 19	RE
Miners boost Australian shares; NZ cenbank keeps rates steady	Apr. 10	RE
New Zealand shares hold gains as c.bank expectedly holds rate; Aussie shares up	Apr. 09	RE
Australian shares rise on mining and healthcare boost; US CPI data, RBNZ in focus	Apr. 09	RE
Australian shares end higher as miners surge; US CPI in focus	Apr. 09	RE
Australian shares fall as financials and healthcare stocks drag	Apr. 02	RE
Australian shares hit record high; RBA cautious on inflation	Apr. 01	RE
Australian shares inch higher; inflation data reinforces subdued rate-cut view	Mar. 26	RE
CSL Prices $1.25 Billion Corporate Bonds Offering	Mar. 26	MT
Miners, healthcare firms push Australia stocks higher	Mar. 25	RE
Australian shares fall as miners, banks weigh	Mar. 10	RE

Chart CSL Limited

Duration

Period

More charts

Company Profile

CSL Limited is an Australia-based biotechnology company. The Companyâs areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Companyâs segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q4 2024 Earnings Release

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for CSL Limited

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

185.1 USD

Average target price

199.6 USD

Spread / Average Target

+7.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-12.32%	33.03B
UCB	+52.41%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-17.39%	15.12B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.9B
INNOVENT BIOLOGICS, INC.	-7.72%	8.22B

Biopharmaceuticals

CSL Limited

Equities

CSL

AU000000CSL8

Pharmaceuticals

CSL Limited Reports Earnings Results for the Half Year Ended December 31, 2023

EPS Revisions